Nephrol Dial Transplant (2000) 15: 1827-1834
© 2000 European Renal Association-European Dialysis and Transplant Association
Catalytically active iron and bacterial growth in serum of haemodialysis patients after i.v. iron–saccharate administration
1 Finnish Red Cross Blood Transfusion Service and 2 Division of Nephrology, Department of Medicine, Helsinki University Hospital, Helsinki, Finland
Background. I.v. iron is commonly administered to haemodialysis patients suffering from anaemia to improve their response to erythropoietin therapy. It has been unclear whether routinely used doses of i.v. iron preparations could result in iron release into plasma in amounts exceeding the iron binding capacity of transferrin. Here, we have studied the effect of 100 mg of iron saccharate given as an i.v. injection on transferrin saturation and the appearance of potentially harmful catalytically active iron.
Methods. We followed serum iron, transferrin and transferrin-saturation before and 5–210 min after administration of iron saccharate in 12 patients on chronic haemodialysis due to end-stage renal disease. We measured catalytically active iron by the bleomycin-detectable iron (BDI) assay and transferrin iron forms by urea gel electrophoresis, and studied iron-dependent growth of Staphylococcus epidermidis inoculated into the serum samples in vitro.
Results. The iron saccharate injection resulted in full transferrin saturation and appearance of BDI in the serum in seven out of the 12 patients. BDI appeared more often in patients with a low serum transferrin concentration, but it was not possible to identify patients at risk based on serum transferrin or ferritin level before i.v. iron. The average transferrin saturation and BDI level increased until the end of the follow-up time of 3.5 h. The appearance of BDI resulted in loss of the ability of patient serum to resist the growth of S. epidermidis, which was restored by adding iron-free apotransferrin to the serum. Iron saccharate, added to serum in vitro, released only little iron and promoted only slow bacterial growth, but caused falsely high transferrin saturation by one routinely used serum iron assay.
Conclusions. The results indicate that 100 mg of iron saccharate often leads to transferrin oversaturation and the presence of catalytically active iron within 3.5 h after i.v. injection. As catalytically active iron is potentially toxic and may promote bacterial growth, it may be recommendable to use dosage regimens for i.v. iron that would not cause transferrin oversaturation.
Keywords: bleomycin-detectable iron; haemodialysis; iron saccharate; Staphylococcus epidermidis; transferrin saturation
Correspondence and offprint requests to: Jaakko Parkkinen, MD, Finnish Red Cross Blood Transfusion Service, Kivihaantie 7, FIN-00310 Helsinki, Finland.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  A. B. Pai and T. A. Conner Oxidative Stress and Inflammation in Chronic Kidney Disease: Role of Intravenous Iron and Vitamin D Journal of Pharmacy Practice, June 1, 2008; 21(3): 214 - 224. [Abstract] [PDF]
|
|
|
|
 |
|
 N. Ternes, B. Scheiber-Mojdehkar, G. Landgraf, H. Goldenberg, and B. Sturm Iron availability and complex stability of iron hydroxyethyl starch and iron dextran a comparative in vitro study with liver cells and macrophages Nephrol. Dial. Transplant., October 1, 2007; 22(10): 2824 - 2830. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. H. Horl Clinical Aspects of Iron Use in the Anemia of Kidney Disease J. Am. Soc. Nephrol., February 1, 2007; 18(2): 382 - 393. [Full Text] [PDF]
|
|
|
|
|
|
G. Guz, G. L. Glorieux, R. De Smet, M.-A. F. Waterloos, R. C. Vanholder, and A. W. Dhondt Impact of iron sucrose therapy on leucocyte surface molecules and reactive oxygen species in haemodialysis patients Nephrol. Dial. Transplant., October 1, 2006; 21(10): 2834 - 2840. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Singh, J. Reed, S. Noble, J. L. Cangiano, D. B. Van Wyck, and for the United States Iron Sucrose (Venofer) Clini Effect of Intravenous Iron Sucrose in Peritoneal Dialysis Patients Who Receive Erythropoiesis-Stimulating Agents for Anemia: A Randomized, Controlled Trial Clin. J. Am. Soc. Nephrol., May 1, 2006; 1(3): 475 - 482. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Michelis, S. Sela, and B. Kristal Intravenous iron-gluconate during haemodialysis modifies plasma {beta}2-microglobulin properties and levels Nephrol. Dial. Transplant., September 1, 2005; 20(9): 1963 - 1969. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H Zotter, N Robinson, M Zorzoli, L Schattenberg, M Saugy, and P Mangin Abnormally high serum ferritin levels among professional road cyclists Br. J. Sports Med., December 1, 2004; 38(6): 704 - 708. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. R. Aronoff Safety of Intravenous Iron in Clinical Practice: Implications for Anemia Management Protocols J. Am. Soc. Nephrol., December 1, 2004; 15(suppl_2): S99 - S106. [Full Text] [PDF]
|
|
|
|
|
|
D. B. Van Wyck Labile Iron: Manifestations and Clinical Implications J. Am. Soc. Nephrol., December 1, 2004; 15(suppl_2): S107 - S111. [Full Text] [PDF]
|
|
|
|
|
|
B. Scheiber-Mojdehkar, B. Lutzky, R. Schaufler, B. Sturm, and H. Goldenberg Non-Transferrin-Bound Iron in the Serum of Hemodialysis Patients Who Receive Ferric Saccharate: No Correlation to Peroxide Generation J. Am. Soc. Nephrol., June 1, 2004; 15(6): 1648 - 1655. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Van Wyck, J. Anderson, and K. Johnson Labile iron in parenteral iron formulations: a quantitative and comparative study Nephrol. Dial. Transplant., March 1, 2004; 19(3): 561 - 565. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Sengoelge, J. Kletzmayr, I. Ferrara, A. Perschl, W. H. Horl, and G. Sunder-Plassmann Impairment of Transendothelial Leukocyte Migration by Iron Complexes J. Am. Soc. Nephrol., October 1, 2003; 14(10): 2639 - 2644. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Michelis, R. Gery, S. Sela, R. Shurtz-Swirski, N. Grinberg, T. Snitkovski, S. M. Shasha, and B. Kristal Carbonyl stress induced by intravenous iron during haemodialysis Nephrol. Dial. Transplant., May 1, 2003; 18(5): 924 - 930. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. von Bonsdorff, E. Lindeberg, L. Sahlstedt, J. Lehto, and J. Parkkinen Bleomycin-detectable Iron Assay for Non-Transferrin-bound Iron in Hematologic Malignancies Clin. Chem., February 1, 2002; 48(2): 307 - 314. [Abstract] [Full Text] [PDF]
|
|